null

SMILES: OC(=O)CC(NC(=O)C1CCN(CC1)C(=O)CCCNC1=NCCN1)c1cccnc1

InChI Key: InChIKey=ODBUGWRTYJJAGU-UHFFFAOYSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 50153561   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Integrin alpha-V/beta-3 (Homo sapiens (Human))	BDBM50153561 (3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...) Show SMILES OC(=O)CC(NC(=O)C1CCN(CC1)C(=O)CCCNC1=NCCN1)c1cccnc1 |t:21| Show InChI InChI=1S/C21H30N6O4/c28-18(4-2-8-23-21-24-9-10-25-21)27-11-5-15(6-12-27)20(31)26-17(13-19(29)30)16-3-1-7-22-14-16/h1,3,7,14-15,17H,2,4-6,8-13H2,(H,26,31)(H,29,30)(H2,23,24,25)	PDB UniProtKB/SwissProt antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	45.7	n/a	n/a	n/a	n/a	n/a	n/a
Johnson & Johnson Pharmaceutical Research and Development Curated by ChEMBL					Assay Description Inhibition of human vitronectin binding to immobilized Alpha v beta-3				Bioorg Med Chem Lett 14: 5227-32 (2004) Article DOI: 10.1016/j.bmcl.2004.06.061 BindingDB Entry DOI: 10.7270/Q2TH8M5Z
					More data for this Ligand-Target Pair
Integrin alpha-V/beta-3 (Homo sapiens (Human))	BDBM50153561 (3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...) Show SMILES OC(=O)CC(NC(=O)C1CCN(CC1)C(=O)CCCNC1=NCCN1)c1cccnc1 |t:21| Show InChI InChI=1S/C21H30N6O4/c28-18(4-2-8-23-21-24-9-10-25-21)27-11-5-15(6-12-27)20(31)26-17(13-19(29)30)16-3-1-7-22-14-16/h1,3,7,14-15,17H,2,4-6,8-13H2,(H,26,31)(H,29,30)(H2,23,24,25)	PDB UniProtKB/SwissProt antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	19	n/a	n/a	n/a	n/a	n/a	n/a
Johnson & Johnson Pharmaceutical Research and Development Curated by ChEMBL					Assay Description Inhibition of human vitronectin binding to immobilized Alpha v beta-3				Bioorg Med Chem Lett 14: 5227-32 (2004) Article DOI: 10.1016/j.bmcl.2004.06.061 BindingDB Entry DOI: 10.7270/Q2TH8M5Z
					More data for this Ligand-Target Pair
Integrin alpha-IIb/beta-3 (Homo sapiens (Human))	BDBM50153561 (3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...) Show SMILES OC(=O)CC(NC(=O)C1CCN(CC1)C(=O)CCCNC1=NCCN1)c1cccnc1 |t:21| Show InChI InChI=1S/C21H30N6O4/c28-18(4-2-8-23-21-24-9-10-25-21)27-11-5-15(6-12-27)20(31)26-17(13-19(29)30)16-3-1-7-22-14-16/h1,3,7,14-15,17H,2,4-6,8-13H2,(H,26,31)(H,29,30)(H2,23,24,25)	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	1.81E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson & Johnson Pharmaceutical Research and Development Curated by ChEMBL					Assay Description Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3				Bioorg Med Chem Lett 14: 5227-32 (2004) Article DOI: 10.1016/j.bmcl.2004.06.061 BindingDB Entry DOI: 10.7270/Q2TH8M5Z
					More data for this Ligand-Target Pair
Integrin alpha-IIb/beta-3 (Homo sapiens (Human))	BDBM50153561 (3-({1-[4-(4,5-Dihydro-1H-imidazol-2-ylamino)-butyr...) Show SMILES OC(=O)CC(NC(=O)C1CCN(CC1)C(=O)CCCNC1=NCCN1)c1cccnc1 |t:21| Show InChI InChI=1S/C21H30N6O4/c28-18(4-2-8-23-21-24-9-10-25-21)27-11-5-15(6-12-27)20(31)26-17(13-19(29)30)16-3-1-7-22-14-16/h1,3,7,14-15,17H,2,4-6,8-13H2,(H,26,31)(H,29,30)(H2,23,24,25)	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	1.80E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johnson & Johnson Pharmaceutical Research and Development Curated by ChEMBL					Assay Description Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3				Bioorg Med Chem Lett 14: 5227-32 (2004) Article DOI: 10.1016/j.bmcl.2004.06.061 BindingDB Entry DOI: 10.7270/Q2TH8M5Z
					More data for this Ligand-Target Pair